```
=> s ondansetron
L1          1411 ONDANSETRON

=> s l1 and hydrochloride monohydrate
           109789 HYDROCHLORIDE
            21116 MONOHYDRATE
              396 HYDROCHLORIDE MONOHYDRATE
                    (HYDROCHLORIDE(W)MONOHYDRATE)
L2              2 L1 AND HYDROCHLORIDE MONOHYDRATE

=> s ondansetron and methanolate
            1411 ONDANSETRON
             371 METHANOLATE
L3              0 ONDANSETRON AND METHANOLATE

=> d l2 1-2 ibib abs hitstr

L2   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2002 ACS
ACCESSION NUMBER:        2002:353422  CAPLUS
DOCUMENT NUMBER:         136:374797
TITLE:                   Preparation of crystal and solvate forms of
                         ondansetron hydrochloride for use as
                         antiemetics
INVENTOR(S):             Lidor-Hadas, Ramy; Aronhime, Judith; Lifshitz,
                         Revital; Weizel, Shlomit; Niddam, Valerie
PATENT ASSIGNEE(S):      Teva Pharmaceutical Industries Ltd., Israel; Teva
                         Pharmaceuticals USA, Inc.
SOURCE:                  PCT Int. Appl., 46 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2002036558      A2   20020510       WO 2001-US48720  20011030
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
             UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2002030935      A5   20020515       AU 2002-30935    20011030
     US 2002107275      A1   20020808       US 2001-16752    20011030
PRIORITY APPLN. INFO.:                  US 2000-244283P  P  20001030
                                        US 2000-253819P  P  20001129
                                        US 2001-265539P  P  20010131
                                        WO 2001-US48720  W  20011030
AB   The present invention provides novel ondansetron hydrochloride
     cryst. polymorphic forms and solvates. Processes for making and
     interconverting the polymorphic forms are also provided. Further,
     pharmaceutical compns. contg. the novel polymorphic forms and hydrates for
     treating nausea and/or vomiting are described. For example,
     ondansetron base (400 mg) was suspended in 16 mL of a 1:1 mixt. of
     ethanol and isopropanol at room temp. and the suspension was heated to
     reflux to dissolve the ondansetron. After 20 min of stirring at
     reflux, an ethanolic soln. contg. 1.1 equiv of HCl was added. The
     reaction mixt. was stirred at this temp. for an addnl. 10 min. Evapn. of
     the solvent gave ondansetron hydrochloride dihydrate Form A.

L2   ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2002 ACS
ACCESSION NUMBER:        2002:89819  CAPLUS
DOCUMENT NUMBER:         136:139852
TITLE:                   Drugs containing cilansetron for treating
```

non-obs[redacted]pated male patients with irrita[redacted] bowel syndrome

INVENTOR(S): Cautreels, Werner; Steinborn, Claus Rudolf; Krause, Heinz Guenter; Caras, Steven David; Biesheuvel, Egbertus Hendrikus Evert; Plekkenpol, Albertus Hermannus Dirk

PATENT ASSIGNEE(S): Solvay Pharmaceuticals G.m.b.H., Germany

SOURCE: PCT Int. Appl., 10 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002007713	A2	20020131	WO 2001-EP8260	20010718
WO 2002007713	A3	20021114		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10123447	A1	20020207	DE 2001-10123447	20010514
US 2002040033	A1	20020404	US 2001-908735	20010720

PRIORITY APPLN. INFO.:
DE 2000-10036645 A 20000726
DE 2001-10123447 A 20010514
US 2000-220848P P 20000726

AB The invention relates to the use of cilansetron prepns. for treating non-obstipated male patients with irritable bowel syndrome (IBS). Cilansetron is a 5HT3-receptor antagonist; other 5HT3-receptor antagonists can also be used to treat both genders. Thus tablets were prepd. that contained (parts): cilansetron **hydrochloride monohydrate** 4; corn starch 30; lactose 70; Kollidon-25 5; magnesium stearate 2; talc 3.

=> d his

(FILE 'HOME' ENTERED AT 10:34:46 ON 17 DEC 2002)

FILE 'CAPLUS' ENTERED AT 10:34:53 ON 17 DEC 2002
L1 1411 S ONDANSETRON
L2 2 S L1 AND HYDROCHLORIDE MONOHYDRATE
L3 0 S ONDANSETRON AND METHANOLATE

=> d l1 1409-1411 ibib abs hitstr

L1 ANSWER 1409 OF 1411 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1990:69896 CAPLUS

DOCUMENT NUMBER: 112:69896

TITLE: The effects of **ondansetron** (GR38032F) in rats and mice treated subchronically with diazepam

AUTHOR(S): Costall, Brenda; Jones, Brian J.; Kelly, M. Elizabeth; Naylor, Robert J.; Oakley, Nigel R.; Onaivi, Emmanuel S.; Tyers, Michael B.

CORPORATE SOURCE: Sch. Pharm., Univ. Bradford, Bradford, BD7 1DP, UK

SOURCE: Pharmacology, Biochemistry and Behavior (1989), 34(4), 769-78
CODEN: PBBHAU; ISSN: 0091-3057

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Using rat and mouse models of aversive behavior, the properties of the 5-HT3 receptor antagonist **ondansetron** (GR38032F) that are relevant to its proposed use as an anxiolytic agent were investigated.

Tolerance to the disinhibitory properties of diazepam was readily demonstrated in the social interaction test in the rat, but did not occur after subchronic treatment with **ondansetron**. In both the light/dark exploration test in mice and the social interaction test in rats, withdrawal from subchronic treatment with diazepam increased behavior suppression, whereas this was not obsd. with **ondansetron**. The behavioral suppression and wt. loss induced by either the withdrawal of diazepam or the administration of the benzodiazepine receptor antagonist, flumazenil, in animals treated subchronically with diazepam, was prevented or antagonized by diazepam or **ondansetron**. Buspirone was ineffective. It is concluded that, in rats and mice, tolerance to the disinhibitory effects of **ondansetron** does not occur, that withdrawal from subchronic treatment with **ondansetron** is not assocd. with any behavioral disturbances and that **ondansetron** is highly effective in preventing the behavioral suppression and wt. loss following withdrawal from subchronic diazepam treatment. These data suggest that **ondansetron** may have major therapeutic advantages over currently available anxiolytic agents, particularly in patients who have previously received prolonged benzodiazepine therapy.

L1 ANSWER 1410 OF 1411 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1990:55689 CAPLUS
DOCUMENT NUMBER: 112:55689
TITLE: Aromatic thiazole derivatives: structurally novel and selective serotonin-3 receptor antagonists
AUTHOR(S): Nagel, Arthur A.; Rosen, Terry; Rizzi, James; Daffeh, June; Guarino, Karen; Nowakowski, Jolanta; Vincent, Lawrence A.; Heym, James; McLean, Stafford; et al.
CORPORATE SOURCE: Dep. Med. Chem., Pfizer Cent. Res., Groton, CT, 06340, USA
SOURCE: Journal of Medicinal Chemistry (1990), 33(1), 13-16
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 112:55689
GI



I



II

AB This report discloses the discovery of a novel series of potent serotonin-3 5-HT3 antagonists, represented by prototypical structures I and II, in which a thiazole ring system appears to mimic the ester functionality in ICS-205-930 and the carbonyl moiety in **ondansetron**. Furthermore, removal of the 5(4)-Me group from the imidazole functionality in compds. I and II causes the resulting compds. to display an initial bradycardia response in the von Bezold-Jarisch reflex, similar to the known 5-HT3 agonist 2-methylserotonin.

L1 ANSWER 1411 OF 1411 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1990:49238 CAPLUS
DOCUMENT NUMBER: 112:49238
TITLE: 5-HT3 receptors mediate inhibition of acetylcholine release in cortical tissue
AUTHOR(S): McLean, Stafford; Rosen, Terry
CORPORATE SOURCE: Pfizer Cent. Res., Groton, CT, USA
SOURCE: Chemtracts: Organic Chemistry (1989), 2(5), 325-7
CODEN: CMOCEI; ISSN: 0895-4445
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Based on the results of a series of in vitro studies, it was shown that activation of 5-HT3 receptors can reduce the evoked release of acetylcholine from the cerebral cortex. Furthermore, it was demonstrated that the selective 5-HT3 antagonists **ondansetron** and zacopride block the inhibitory effect of 2-methylserotonin (5-HT3 agonist) on K-stimulated [3H]acetylcholine release.